

Prof. Dr. Peter Schirmacher
Director Institute of Pathology, Heidelberg



Institute of Pathology
Im Neuenheimer Feld 220
69120 Heidelberg

06221 56 2601 (phone)
06221 56 5251 (fax)
peter.schirmacher@med.uni-heidelberg.de

SCIENTIFIC VITA

1981-1987	Study of Medicine, University of Mainz
1987	MD-Thesis (magna cum laude, Institute of Physiology, University of Mainz)
1987-1989/	
1991-1998	Institute of Pathology, University of Mainz
1989-1991	Postdoctoral Research Fellowship (DFG) Liver Research Center, Albert Einstein College of Medicine, New York (Prof. D.A. Shafritz)
	PhD-Study (Molecular Biology) Albert Einstein College, New York
since 1992	Scientific Research Group leader
1995	Board Certification Pathology
1996	Board Certification Molecular Pathology and Habilitation
1996-1998	Managing board DFG-SFB 519
1998-2004	Full Professor of Pathology (C3) and Deputy Director, Institute of Pathology, University of Cologne
2001-2004	Managing board 'Center for Molecular Medicine Cologne' (CMMC)
since 2004	Professor of Pathology (C4) and Director, Institute of Pathology, University of Heidelberg
since 2004	Managing board Tumorzentrum Heidelberg/Mannheim
since 2006	Board German Association for Study of the Liver; designated president (2008/09)

AWARDS:

Johannes Gutenberg Award (1988); Boehringer Ingelheim Award (1997)

FIELDS OF INTEREST:

Molecular and morphological digestive tract carcinogenesis (especially liver and pancreas; prognostic, diagnostic, and therapeutic targets); Tumorigenic role of growth factor mediated signalling processes (IGF, WNT, HGF/MET); Chronic liver diseases and their role in initiating hepatocarcinogenesis (especially chronic viral hepatitis); molecular pathological diagnostics; tumor banking; virtual microscopy

SELECTED PUBLICATIONS (SINCE 2000)

Choudhury AR, Ju Z, Djojosebroto MW, Schienke A, Lechel A, Schaetzlein S, Jiang H, Stepczynska A, Wang C, Buer J, Lee HW, von Zglinicki T, Ganzer A, Schirmacher P, Nakauchi H, Rudolph KL (2007). Cdkn1a deletion improves stem cell function and lifespan of mice with dysfunctional telomeres without accelerating cancer formation. **Nat Genet** 39, 99-105

Kern MA, Haugg AM, Koch AF, Schilling T, Breuhahn K, Walczak H, Fleischer B, Trautwein C, Michalski C, Schulze-Bergkamen H, Friess H, Stremmel W, Krammer PH, Schirmacher P, Muller M (2006). Cyclooxygenase-2 inhibition induces apoptosis signaling via death receptors and mitochondria in hepatocellular carcinoma. **Cancer Res** 66, 7059-7066.

Breuhahn K, Longerich T, Schirmacher P (2006). Dysregulation of growth factor signaling in human hepatocellular carcinoma. **Oncogene** 25, 3787-3800.

Muller-Decker K, Furstenberger G, Annan N, Kucher D, Pohl-Arnold A, Steinbauer B, Esposito I, Chiblak S, Friess H, Schirmacher P, Berger I (2006). Preinvasive duct-derived neoplasms in pancreas of keratin 5-promoter cyclooxygenase-2 transgenic mice. **Gastroenterology** 130, 2165-2178.

Esposito I, Penzel R, Chaib-Harrireche M, Barcena U, Bergmann F, Riedl S, Kaye H, Giese N, Kleeff J, Friess H, Schirmacher P (2006). Tenascin C and annexin II expression in the process of pancreatic carcinogenesis. **J Pathol** 208, 673-685.

Breuhahn K, Vreden S, Haddad R, Beckebaum S, Stippel D, Flemming P, Nussbaum T, Caselmann WH, Haab BB, Schirmacher P (2004). Molecular profiling of hepatocellular carcinoma defines mutually exclusive interferon regulation and insulin-like growth factor II overexpression. **Cancer Res** 64, 6058-6064

Prange W, Breuhahn K, Fischer F, Zilkens C, Pietsch T, Petmecky K, Eilers R, Dienes HP, Schirmacher P (2003). Beta-catenin accumulation in progression of human hepatocarcinogenesis correlates with loss of E-cadherin, accumulation of p53, but not with expression of conventional WNT-1 target genes. **J Pathol**, 201, 250-259

Kern MA, Schubert D, Sahi D, Schöneweiß MM, Moll I, Haugg A, Dienes HP, Breuhahn K, Schirmacher P (2002). Proapoptotic and antiproliferative potential of selective cyclooxygenase-2 inhibitors in human liver tumor cells. **Hepatology** 36, 885-894

Kern MA, Breuhahn K, Schirmacher P (2002). Molecular pathogenesis of human hepatocellular carcinoma. **Adv Cancer Res** 86, 67-112

Beilmann M, Vande Woude GF, Dienes HP, Schirmacher P (2000). Hepatocyte growth factor-stimulated invasiveness of monocytes. **Blood** 95, 3964-3969